Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LXRX Lexicon Pharmaceuticals

Trading 01-22 10:23:49 EST

1.66

+0.10

+6.32%

High1.77	Low1.52	Vol2.60M
Open1.55	D1 Closing1.56	Amplitude16.03%
Mkt Cap602.73M	Tradable Cap305.00M	Total Shares363.40M
T/O4.38M	T/O Rate1.41%	Tradable Shares183.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LXRX","market":"US","secType":"STK","nameCN":"Lexicon Pharmaceuticals","latestPrice":1.6586,"timestamp":1769095419119,"preClose":1.56,"halted":0,"volume":2595874,"delay":0,"changeRate":0.06320512820512822,"floatShares":183889453,"shares":363398680,"eps":-0.189102,"marketStatus":"Trading","change":0.0986,"latestTime":"01-22 10:23:49 EST","open":1.55,"high":1.77,"low":1.52,"amount":4377632.8515814,"amplitude":0.160256,"askPrice":1.66,"askSize":4150,"bidPrice":1.65,"bidSize":1760,"shortable":3,"etf":0,"ttmEps":-0.189102,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1769115600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":955080000000,"exchange":"NASDAQ","adjPreClose":1.56,"preHourTrading":{"tag":"盘前","latestPrice":1.55,"preClose":1.56,"latestTime":"09:27 EST","volume":61523,"amount":94931.3794198,"timestamp":1769092061537,"change":-0.01,"changeRate":-0.00641,"amplitude":0.051282},"postHourTrading":{"tag":"盘后","latestPrice":1.57,"preClose":1.56,"latestTime":"19:59 EST","volume":35570,"amount":54991.3555,"timestamp":1769043578952,"change":0.01,"changeRate":0.00641,"amplitude":0.038462},"volumeRatio":5.188609,"impliedVol":1.0182,"impliedVolPercentile":0.1952},"requestUrl":"/m/hq/s/LXRX/tweets","defaultTab":"tweets","newsList":[{"id":"2605867214","title":"BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2605867214","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605867214?lang=en_us&edition=fundamental","pubTime":"2026-01-21 23:49","pubTimestamp":1769010597,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers CompaniesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL6N3YM11M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","EXE","HL","LNG","AVR","CBIO","CDE","UAL","BIOA","ALGS","LXRX","LU2430703095.HKD","NNE","LSTA","SLB","AMBQ","NEM","OCGN","IE00B775SV38.USD","LPTH","WMB","BK4533","OCUL","LU0985481810.HKD","ALB","SCHW","CNX","LBRT","IE00BBT3K403.USD","F","NATH","DXC","PLD","TFC","JNJ","HAL","KHC","LUCD","TRV","INTC","ROCK","BKR","IE00B29SXL02.USD","BK4141","TDY","GM","LU0154245673.USD"],"gpt_icon":1},{"id":"2605483858","title":"BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous","url":"https://stock-news.laohu8.com/highlight/detail?id=2605483858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605483858?lang=en_us&edition=fundamental","pubTime":"2026-01-21 22:25","pubTimestamp":1769005524,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s FamousEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL6N3YM0P9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2272731782.SGD","PLD","RIO.AU","LU0347712357.USD","NATH","LU1201861165.SGD","FCX","BK4145","NEM","LPTH","ARM","BKR","RIO.UK","SG9999002232.USD","PAVM","IE0004091025.USD","LU1023059063.AUD","LU1066051811.HKD","LU0130103400.USD","SCHW","IE00BLSP4452.SGD","UAL","TDY","HL","TEL","LBRT","LU0417517546.SGD","JNJ","OCUL","TFC","ALB","CDE","BIOA","LU0079474960.USD","TRV","CBIO","LXRX","NFLX","ROCK","SG9999002224.SGD","LU2362540622.SGD","KHC","AVR","LU2272731600.USD","HAL","LUCD","LU2463526074.USD","BHP.AU","SLB"],"gpt_icon":0},{"id":"2605548100","title":"BUZZ-Lexicon rises as FDA clears late‑stage test of diabetic nerve‑pain drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2605548100","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605548100?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:42","pubTimestamp":1769002979,"startTime":"0","endTime":"0","summary":"BUZZ-Lexicon rises as FDA clears latestage test of diabetic nervepain drug** Shares of drug developer Lexicon Pharmaceuticals LXRX.O rise 2.16% to $1.34 premarket** Co says U.S. FDA cleared the latestage trial of its experimental drug pilavapadin for diabetic nerve pain** Diabetic nerve pain is a condition caused by longterm high blood sugar that damages nerves** Co says the 12week study will test a 10 mg daily dose of the experimental nonopioid drug against a placebo** LXRX's pilavapadin blocks a protein involved in pain signalling, and early tests showed reduced pain without affecting opioid pathways** FDA did not ask for additional studies, co says** Shares up ~56% in 2025  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL4N3YM1BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139","BK4007"],"gpt_icon":0},{"id":"2605810777","title":"Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2605810777","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605810777?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:30","pubTimestamp":1769002243,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration  for pilavapadin in the treatment of diabetic peripheral neuropathic pain . The FDA raised no objections to advancing pilavapadin into Phase 3 development. The Phase 3 program will include two placebo-controlled, 12-week, two-arm registrational studies evaluating a 10 mg daily dose compared to placebo. The primary endpoint will be the change in average daily pain score from baseline to Week 12. Results of the Phase 3 studies have not yet been presented and are expected in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL3tTQKw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210150020.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014005.SGD","BK4007","BK4139","SG9999014021.USD","BK4112","BK4585","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LXRX","NDAQ","BK4588"],"gpt_icon":0},{"id":"2605107762","title":"Lexicon Pharmaceuticals Inc - FDA Raised No Objections to Advancement of Pilavapadin Into Phase 3 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2605107762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605107762?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:30","pubTimestamp":1769002201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUA1JWTPT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXRX","BK4007"],"gpt_icon":0},{"id":"2605077931","title":"Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2605077931","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605077931?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:30","pubTimestamp":1769002201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUA1JWTPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","LXRX"],"gpt_icon":0},{"id":"2605117177","title":"Lexicon Pharmaceuticals: Global INPEFA Expansion and Late-Stage Pipeline Catalysts Support Buy Rating and $4 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2605117177","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605117177?lang=en_us&edition=fundamental","pubTime":"2026-01-21 00:16","pubTimestamp":1768925794,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, with a price target of $4.00....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/lexicon-pharmaceuticals-global-inpefa-expansion-and-late-stage-pipeline-catalysts-support-buy-rating-and-4-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/lexicon-pharmaceuticals-global-inpefa-expansion-and-late-stage-pipeline-catalysts-support-buy-rating-and-4-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","SSI"],"gpt_icon":0},{"id":"2603996826","title":"Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Lexicon Pharmaceuticals (LXRX) and Alkermes (ALKS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603996826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603996826?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:01","pubTimestamp":1768568480,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Centessa Pharmaceuticals (CNTA – Research Report), L...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-centessa-pharmaceuticals-cnta-lexicon-pharmaceuticals-lxrx-and-alkermes-alks-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-centessa-pharmaceuticals-cnta-lexicon-pharmaceuticals-lxrx-and-alkermes-alks-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","XLV","BK4137","ALKS","BK4139","BK4535","BK4539","HCSG","LU0029874061.USD","BK4585","BK4007","BK4581","LABU","LXRX","XBI","CNTA","BK4588"],"gpt_icon":0},{"id":"2602122455","title":"Lexicon Pharmaceuticals Announces Pipeline Progress and Milestone Payment at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602122455","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602122455?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:31","pubTimestamp":1768221092,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. provided a business and pipeline update at the 44th Annual J.P. Morgan Healthcare Conference. The company reported that enrollment for the SONATA-HCM trial is expected to be completed in 2026, with topline data anticipated in 2027. Lexicon triggered a $10 million milestone payment from a licensing agreement with Novo Nordisk for LX9851. The company also stated that Zynquista is on track for NDA resubmission and potential approval in 2026. Additional updates included progress on pilavapadin for neuropathic pain, following a productive End-of-Phase 2 meeting with the FDA in late 2025, and ongoing partnership discussions to advance the therapy globally. Lexicon also highlighted international expansion of the sotagliflozin program through Viatris, with regulatory approval received in the United Arab Emirates and applications submitted in Canada, Australia, and New Zealand in 2025. Further regulatory submissions and approvals are expected in key markets througho","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6vN2LR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","LXRX","BK4112","SG9999014039.USD","SG9999014021.USD","SG9999014013.SGD","SG9999014005.SGD","BK4007","IE00BKPKM429.USD","NDAQ","LU2210149790.SGD","BK4588","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2602195512","title":"Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44TH Annual J.p. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602195512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602195512?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA5T8NFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXRX","BK4139","BK4007"],"gpt_icon":0},{"id":"2602376013","title":"Lexicon Pharmaceuticals Hosts Roundtable on Expanding Access to Non-Opioid Pain Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376013","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376013?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965416,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. convened an in-person Roundtable in Washington, D.C. in October 2025, bringing together diverse stakeholders to address the unmet needs of people living with chronic pain. The event focused on accelerating innovation and expanding access to novel non-opioid therapies, aiming to shape legislative priorities and improve patient outcomes. The findings from this Roundtable are summarized in a recently published White Paper titled \"Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain.\". Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on January 09, 2026, and is solely responsibl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL2VTZFM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU2210150020.SGD","BK4139","SG9999014021.USD","BK4007","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","LXRX","NDAQ","LU0314104364.USD","BK4112","SG9999014013.SGD","BK4588","LU2095319765.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2590587065","title":"Lexicon Pharmaceuticals Signs Exclusive Global Licensing Agreement for LX9851 with Novo Nordisk","url":"https://stock-news.laohu8.com/highlight/detail?id=2590587065","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590587065?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:30","pubTimestamp":1765373416,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. announced that in March 2025, it entered into an exclusive, worldwide licensing agreement for LX9851 with Novo Nordisk. The agreement covers LX9851, an investigational non-incretin, oral, small molecule ACSL5 inhibitor being developed for obesity and chronic weight management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL27QbFm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","BK4007","SG9999014013.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4112","BK4139","SG9999014039.USD","LU2210149790.SGD","BK4588","LXRX","NDAQ","IE00BGHQF748.EUR","LU2095319765.USD"],"gpt_icon":1},{"id":"2590580761","title":"Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2590580761","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590580761?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:30","pubTimestamp":1765373400,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, Texas, Dec.  10, 2025  (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.(Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203150/0/en/Lexicon-Pharmaceuticals-Announces-Publication-of-Preclinical-Data-in-the-Journal-of-the-Endocrine-Society-on-Acyl-CoA-Synthetase-5-ACSL5-Reinforcing-the-Scientific-Rationale-for-LX.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LXRX"],"gpt_icon":0},{"id":"2589689063","title":"Lexicon Pharmaceuticals to Present New Sotagliflozin Data on Adipose Distribution in Non-Diabetic HFpEF Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2589689063","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589689063?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:30","pubTimestamp":1764941412,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. announced that clinical data on the effect of sotagliflozin on adipose tissue distribution in non-diabetic patients will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum , scheduled for December 8-10, 2025, in Washington, D.C. The data are derived from the SOTA-P-CARDIA trial, a prospective, randomized, double-blind, placebo-controlled study enrolling patients with heart failure with preserved ejection fraction  and conducted by Mount Sinai Medical Center. The presentation, titled \"Effect of sotagliflozin on adipose distribution in non-diabetic patients with HFpEF,\" will be delivered by Juan Jose Badimon, Ph.D., on December 8, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL8lCL7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NDAQ","BK4585","BK4007","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LXRX","IE00BKPKM429.USD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2586475460","title":"Lexicon Pharmaceuticals to Present at Piper Sandler and Evercore Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2586475460","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586475460?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:30","pubTimestamp":1764077415,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. will participate in two upcoming investor conferences in December. The company is scheduled for a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET, and will also attend the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET. Live events and replays of the presentations will be available on the Events page of the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL75Y0dK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","LU0314104364.USD","BK4127","LU2210149790.SGD","BK4139","BK4588","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4585","NDAQ","LU2210150020.SGD","LU2095319765.USD","PIPR","BK4007","IE00B64PRP62.GBP","EVR","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2584578929","title":"Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584578929","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584578929?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:00","pubTimestamp":1763571626,"startTime":"0","endTime":"0","summary":"Nov 7 (Reuters) - Lexicon Pharmaceuticals Inc ::*LEXICON PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO $75 MILLION OF COMMON STOCK - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202523:07:41 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDbjqp58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX","BK4007"],"gpt_icon":0},{"id":"2584926732","title":"Lexicon Pharmaceuticals Q3 EPS USD -0.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926732","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926732?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:53","pubTimestamp":1763571220,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Lexicon Pharmaceuticals Q3 basic EPS USD -0.04.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202512:00:09.673 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD6G2Z7p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139","BK4007"],"gpt_icon":0},{"id":"1112567484","title":"Stock Track | Lexicon Pharmaceuticals Surges 5.28% on Upcoming Jefferies Conference Participation","url":"https://stock-news.laohu8.com/highlight/detail?id=1112567484","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112567484?lang=en_us&edition=fundamental","pubTime":"2025-11-12 00:04","pubTimestamp":1762877075,"startTime":"0","endTime":"0","summary":"Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) are soaring 5.28% during Tuesday's intraday trading session, following the company's announcement of its participation in the prestigious Jefferies...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LXRX"],"gpt_icon":0},{"id":"1179883925","title":"Stock Track | Lexicon Pharmaceuticals Soars 5.28% on Upcoming Jefferies Conference Participation","url":"https://stock-news.laohu8.com/highlight/detail?id=1179883925","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179883925?lang=en_us&edition=fundamental","pubTime":"2025-11-12 00:02","pubTimestamp":1762876958,"startTime":"0","endTime":"0","summary":"Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) are soaring 5.28% during Tuesday's intraday trading session, following the announcement of the company's participation in the upcoming Jefferies 2025...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LXRX"],"gpt_icon":0},{"id":"2582361004","title":"Lexicon Pharmaceuticals to Join Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2582361004","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582361004?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:30","pubTimestamp":1762867814,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Inc. will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on November 18, 2025. The event will be available via the Events page on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL6Ng8Pt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2210149790.SGD","BK4112","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","BK4588","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","LU2095319765.USD","LXRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lexpharma.com","stockEarnings":[{"period":"1week","weight":0.2581},{"period":"1month","weight":0.2787},{"period":"3month","weight":0.1143},{"period":"6month","weight":0.4182},{"period":"1year","weight":0.9789},{"period":"ytd","weight":0.3565}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0203},{"period":"6month","weight":0.0758},{"period":"1year","weight":0.1366},{"period":"ytd","weight":0.0051}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.054262},{"month":2,"riseRate":0.4,"avgChangeRate":-0.059177},{"month":3,"riseRate":0.48,"avgChangeRate":-0.019425},{"month":4,"riseRate":0.44,"avgChangeRate":0.012763},{"month":5,"riseRate":0.5,"avgChangeRate":0.029091},{"month":6,"riseRate":0.653846,"avgChangeRate":0.134775},{"month":7,"riseRate":0.5,"avgChangeRate":0.021487},{"month":8,"riseRate":0.269231,"avgChangeRate":-0.025279},{"month":9,"riseRate":0.346154,"avgChangeRate":0.011129},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.006481},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.041818},{"month":12,"riseRate":0.461538,"avgChangeRate":0.062158}],"exchange":"NASDAQ","name":"Lexicon Pharmaceuticals","nameEN":"Lexicon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lexicon Pharmaceuticals,LXRX,Lexicon Pharmaceuticals股票,Lexicon Pharmaceuticals股票老虎,Lexicon Pharmaceuticals股票老虎国际,Lexicon Pharmaceuticals行情,Lexicon Pharmaceuticals股票行情,Lexicon Pharmaceuticals股价,Lexicon Pharmaceuticals股市,Lexicon Pharmaceuticals股票价格,Lexicon Pharmaceuticals股票交易,Lexicon Pharmaceuticals股票购买,Lexicon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lexicon Pharmaceuticals(LXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lexicon Pharmaceuticals(LXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}